Overview
Shintaro Mandai practices in Tokyo, Japan. Mr. Mandai is rated as an Experienced expert by MediFind in the treatment of Gitelman Syndrome. His top areas of expertise are Membranoproliferative Glomerulonephritis, Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease, Nephronophthisis, and Nephrectomy.
His clinical research consists of co-authoring 74 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Gitelman Syndrome.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Autosomal Dominant Polycystic Kidney Disease
- Chronic Kidney DiseaseMr. Mandai isAdvanced. Learn about Chronic Kidney Disease.
- Membranoproliferative Glomerulonephritis
- NephronophthisisMr. Mandai isAdvanced. Learn about Nephronophthisis.
- Polycystic Kidney DiseaseMr. Mandai isAdvanced. Learn about Polycystic Kidney Disease.
- Experienced
- Alport SyndromeMr. Mandai isExperienced. Learn about Alport Syndrome.
- Aortic DissectionMr. Mandai isExperienced. Learn about Aortic Dissection.
- Autosomal Dominant Tubulointerstitial Kidney Disease
- Autosomal Recessive Polycystic Kidney Disease
- Bartter SyndromeMr. Mandai isExperienced. Learn about Bartter Syndrome.
- End-Stage Renal Disease (ESRD)Mr. Mandai isExperienced. Learn about End-Stage Renal Disease (ESRD).